ACCELERON PHARMA INC. (NASDAQ:XLRN) Files An 8-K Other Events

0

ACCELERON PHARMA INC. (NASDAQ:XLRN) Files An 8-K Other Events
Item 8.01 Other Events.

On June 4, 2018, Acceleron Pharma Inc. issued a press release titled "Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the ASCO 2018 Annual Meeting."

A copy of the press release is attached as Exhibit99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01Financial Statements and Exhibits.

(d)Exhibits.


ACCELERON PHARMA INC Exhibit
EX-99.1 2 xlrn-20180605form8xkex991.htm EXHIBIT 99.1 Exhibit Exhibit 99.1 Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the ASCO 2018 Annual Meeting– Multiple patients continue on treatment with clinically meaningful increases in hemoglobin and reduction in red blood cell transfusions surpassing 3 years –– Top-line results from the MEDALIST Phase 3 trial are on track for the middle of 2018 –– COMMANDS Phase 3 trial in first-line,…
To view the full exhibit click here

About ACCELERON PHARMA INC. (NASDAQ:XLRN)

Acceleron Pharma Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutic candidates that are based on mechanisms, which the human body uses to regulate the growth and repair of its cells and tissues. Its therapeutic candidates are used to treat serious and rare diseases. The Company’s pipeline includes Luspatercept, Sotatercept, Dalantercept, ACE-083, ACE-2494, ACE-1332, ACE-3891, ACE-2798, ACE-2536 and ACE-2395. Luspatercept promotes red blood cell production. It is developing Sotatercept for the treatment of chronic kidney disease. Dalantercept treats cancers by inhibiting blood vessel formation by inhibiting signaling through the activin receptor-like kinase (ALK) 1 receptor. ACE-083 is for the treatment of focal muscle disorders. ACE-2494 is designed to treat systemic muscle disorders. ACE-3891, ACE-1332, ACE-2798, ACE-2536 and ACE-2395 are in preclinical stage of development.